腫瘍壊死因子阻害剤の世界市場（～2026年）

• 英文タイトル：Global Tumor Necrosis Factor Inhibitors Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY12765
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、118ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は腫瘍壊死因子阻害剤のグローバル市場について調査・分析したレポートです。種類別（ヒュミラ、エンブレル、レミケード、その他）市場規模、用途別（アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別腫瘍壊死因子阻害剤の競争状況、市場シェア
・世界の腫瘍壊死因子阻害剤市場：種類別市場規模 2015年-2020年（ヒュミラ、エンブレル、レミケード、その他）
・世界の腫瘍壊死因子阻害剤市場：種類別市場規模予測 2021年-2026年（ヒュミラ、エンブレル、レミケード、その他）
・世界の腫瘍壊死因子阻害剤市場：用途別市場規模 2015年-2020年（アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他）
・世界の腫瘍壊死因子阻害剤市場：用途別市場規模予測 2021年-2026年（アルツハイマー病、パーキンソン病、虚血性脳卒中、多発性硬化症、その他）
・北米の腫瘍壊死因子阻害剤市場分析：米国、カナダ
・ヨーロッパの腫瘍壊死因子阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの腫瘍壊死因子阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の腫瘍壊死因子阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの腫瘍壊死因子阻害剤市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：EPIRUS Biopharmaceuticals、Bionovis、CASI Pharmaceuticals、Janssen Biotech、Momenta Pharmaceuticals、GlaxoSmithKline、HanAll Biopharma、Intas Pharmaceuticals、LEO Pharma、Dexa Medica、LG Life Sciences、MedImmune
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Market
The global Tumor Necrosis Factor Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Tumor Necrosis Factor Inhibitors Scope and Market Size
Tumor Necrosis Factor Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Tumor Necrosis Factor Inhibitors market is segmented into
Humira
Enbrel
Remicade
Others

Segment by Application, the Tumor Necrosis Factor Inhibitors market is segmented into
Alzheimer’s Diseases
Parkinson’s Diseases
Ischemic Stroke
Multiple Sclerosis
Others

Regional and Country-level Analysis
The Tumor Necrosis Factor Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the Tumor Necrosis Factor Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Tumor Necrosis Factor Inhibitors Market Share Analysis
Tumor Necrosis Factor Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Tumor Necrosis Factor Inhibitors business, the date to enter into the Tumor Necrosis Factor Inhibitors market, Tumor Necrosis Factor Inhibitors product introduction, recent developments, etc.

The major vendors covered:
EPIRUS Biopharmaceuticals
Bionovis
CASI Pharmaceuticals
Janssen Biotech
Momenta Pharmaceuticals
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
Dexa Medica
LG Life Sciences
MedImmune

レポート目次

1 Study Coverage
1.1 Tumor Necrosis Factor Inhibitors Product Introduction
1.2 Market Segments
1.3 Key Tumor Necrosis Factor Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type
1.4.2 Humira
1.4.3 Enbrel
1.4.4 Remicade
1.4.5 Others
1.5 Market by Application
1.5.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application
1.5.2 Alzheimer’s Diseases
1.5.3 Parkinson’s Diseases
1.5.4 Ischemic Stroke
1.5.5 Multiple Sclerosis
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Tumor Necrosis Factor Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global Tumor Necrosis Factor Inhibitors Revenue 2015-2026
2.1.2 Global Tumor Necrosis Factor Inhibitors Sales 2015-2026
2.2 Global Tumor Necrosis Factor Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Tumor Necrosis Factor Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Tumor Necrosis Factor Inhibitors Competitor Landscape by Players
3.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers
3.1.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
3.2.1 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Tumor Necrosis Factor Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Revenue in 2019
3.2.5 Global Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Tumor Necrosis Factor Inhibitors Price by Manufacturers
3.4 Tumor Necrosis Factor Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 Tumor Necrosis Factor Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Tumor Necrosis Factor Inhibitors Market Size by Type (2015-2020)
4.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020)
4.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Type (2015-2020)
4.1.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Tumor Necrosis Factor Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Tumor Necrosis Factor Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Tumor Necrosis Factor Inhibitors Market Size by Application (2015-2020)
5.1.1 Global Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020)
5.1.2 Global Tumor Necrosis Factor Inhibitors Revenue by Application (2015-2020)
5.1.3 Tumor Necrosis Factor Inhibitors Price by Application (2015-2020)
5.2 Tumor Necrosis Factor Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global Tumor Necrosis Factor Inhibitors Price Forecast by Application (2021-2026)

6 North America
6.1 North America Tumor Necrosis Factor Inhibitors by Country
6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Country
6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
6.3 North America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

7 Europe
7.1 Europe Tumor Necrosis Factor Inhibitors by Country
7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Country
7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
7.3 Europe Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Tumor Necrosis Factor Inhibitors by Region
8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region
8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

9 Latin America
9.1 Latin America Tumor Necrosis Factor Inhibitors by Country
9.1.1 Latin America Tumor Necrosis Factor Inhibitors Sales by Country
9.1.2 Latin America Tumor Necrosis Factor Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
9.3 Central & South America Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors by Country
10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country
10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Facts & Figures by Application

11 Company Profiles
11.1 EPIRUS Biopharmaceuticals
11.1.1 EPIRUS Biopharmaceuticals Corporation Information
11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.1.5 EPIRUS Biopharmaceuticals Related Developments
11.2 Bionovis
11.2.1 Bionovis Corporation Information
11.2.2 Bionovis Description and Business Overview
11.2.3 Bionovis Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Products Offered
11.2.5 Bionovis Related Developments
11.3 CASI Pharmaceuticals
11.3.1 CASI Pharmaceuticals Corporation Information
11.3.2 CASI Pharmaceuticals Description and Business Overview
11.3.3 CASI Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.3.5 CASI Pharmaceuticals Related Developments
11.4 Janssen Biotech
11.4.1 Janssen Biotech Corporation Information
11.4.2 Janssen Biotech Description and Business Overview
11.4.3 Janssen Biotech Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Products Offered
11.4.5 Janssen Biotech Related Developments
11.5 Momenta Pharmaceuticals
11.5.1 Momenta Pharmaceuticals Corporation Information
11.5.2 Momenta Pharmaceuticals Description and Business Overview
11.5.3 Momenta Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.5.5 Momenta Pharmaceuticals Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 HanAll Biopharma
11.7.1 HanAll Biopharma Corporation Information
11.7.2 HanAll Biopharma Description and Business Overview
11.7.3 HanAll Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Products Offered
11.7.5 HanAll Biopharma Related Developments
11.8 Intas Pharmaceuticals
11.8.1 Intas Pharmaceuticals Corporation Information
11.8.2 Intas Pharmaceuticals Description and Business Overview
11.8.3 Intas Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.8.5 Intas Pharmaceuticals Related Developments
11.9 LEO Pharma
11.9.1 LEO Pharma Corporation Information
11.9.2 LEO Pharma Description and Business Overview
11.9.3 LEO Pharma Sales, Revenue and Gross Margin (2015-2020)
11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Products Offered
11.9.5 LEO Pharma Related Developments
11.10 Dexa Medica
11.10.1 Dexa Medica Corporation Information
11.10.2 Dexa Medica Description and Business Overview
11.10.3 Dexa Medica Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Products Offered
11.10.5 Dexa Medica Related Developments
11.1 EPIRUS Biopharmaceuticals
11.1.1 EPIRUS Biopharmaceuticals Corporation Information
11.1.2 EPIRUS Biopharmaceuticals Description and Business Overview
11.1.3 EPIRUS Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
11.1.5 EPIRUS Biopharmaceuticals Related Developments
11.12 MedImmune
11.12.1 MedImmune Corporation Information
11.12.2 MedImmune Description and Business Overview
11.12.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
11.12.4 MedImmune Products Offered
11.12.5 MedImmune Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Tumor Necrosis Factor Inhibitors Market Estimates and Projections by Region
12.1.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Tumor Necrosis Factor Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Tumor Necrosis Factor Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Tumor Necrosis Factor Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Tumor Necrosis Factor Inhibitors Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Tumor Necrosis Factor Inhibitors Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Tumor Necrosis Factor Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Tumor Necrosis Factor Inhibitors Market Segments
Table 2. Ranking of Global Top Tumor Necrosis Factor Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Humira
Table 5. Major Manufacturers of Enbrel
Table 6. Major Manufacturers of Remicade
Table 7. Major Manufacturers of Others
Table 8. Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Tumor Necrosis Factor Inhibitors Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Tumor Necrosis Factor Inhibitors Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Regions (2015-2020)
Table 12. Global Tumor Necrosis Factor Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Tumor Necrosis Factor Inhibitors Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Tumor Necrosis Factor Inhibitors Sales Share by Manufacturers (2015-2020)
Table 15. Global Tumor Necrosis Factor Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Tumor Necrosis Factor Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Inhibitors as of 2019)
Table 17. Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Tumor Necrosis Factor Inhibitors Price (2015-2020) (USD/Pcs)
Table 20. Tumor Necrosis Factor Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Tumor Necrosis Factor Inhibitors Product Type
Table 22. Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 25. Global Tumor Necrosis Factor Inhibitors Sales Share by Type (2015-2020)
Table 26. Global Tumor Necrosis Factor Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Tumor Necrosis Factor Inhibitors Revenue Share by Type (2015-2020)
Table 28. Tumor Necrosis Factor Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 30. Global Tumor Necrosis Factor Inhibitors Sales Share by Application (2015-2020)
Table 31. North America Tumor Necrosis Factor Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 32. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2015-2020)
Table 33. North America Tumor Necrosis Factor Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2015-2020)
Table 35. North America Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 36. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Table 37. North America Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 38. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Table 39. Europe Tumor Necrosis Factor Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2015-2020)
Table 41. Europe Tumor Necrosis Factor Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2015-2020)
Table 43. Europe Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Table 45. Europe Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Table 55. Latin America Tumor Necrosis Factor Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Tumor Necrosis Factor Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2015-2020)
Table 59. Latin America Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Table 61. Latin America Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Table 71. EPIRUS Biopharmaceuticals Corporation Information
Table 72. EPIRUS Biopharmaceuticals Description and Major Businesses
Table 73. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. EPIRUS Biopharmaceuticals Product
Table 75. EPIRUS Biopharmaceuticals Recent Development
Table 76. Bionovis Corporation Information
Table 77. Bionovis Description and Major Businesses
Table 78. Bionovis Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Bionovis Product
Table 80. Bionovis Recent Development
Table 81. CASI Pharmaceuticals Corporation Information
Table 82. CASI Pharmaceuticals Description and Major Businesses
Table 83. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. CASI Pharmaceuticals Product
Table 85. CASI Pharmaceuticals Recent Development
Table 86. Janssen Biotech Corporation Information
Table 87. Janssen Biotech Description and Major Businesses
Table 88. Janssen Biotech Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Janssen Biotech Product
Table 90. Janssen Biotech Recent Development
Table 91. Momenta Pharmaceuticals Corporation Information
Table 92. Momenta Pharmaceuticals Description and Major Businesses
Table 93. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. Momenta Pharmaceuticals Product
Table 95. Momenta Pharmaceuticals Recent Development
Table 96. GlaxoSmithKline Corporation Information
Table 97. GlaxoSmithKline Description and Major Businesses
Table 98. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. GlaxoSmithKline Product
Table 100. GlaxoSmithKline Recent Development
Table 101. HanAll Biopharma Corporation Information
Table 102. HanAll Biopharma Description and Major Businesses
Table 103. HanAll Biopharma Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. HanAll Biopharma Product
Table 105. HanAll Biopharma Recent Development
Table 106. Intas Pharmaceuticals Corporation Information
Table 107. Intas Pharmaceuticals Description and Major Businesses
Table 108. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Intas Pharmaceuticals Product
Table 110. Intas Pharmaceuticals Recent Development
Table 111. LEO Pharma Corporation Information
Table 112. LEO Pharma Description and Major Businesses
Table 113. LEO Pharma Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 114. LEO Pharma Product
Table 115. LEO Pharma Recent Development
Table 116. Dexa Medica Corporation Information
Table 117. Dexa Medica Description and Major Businesses
Table 118. Dexa Medica Tumor Necrosis Factor Inhibitors Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 119. Dexa Medica Product
Table 120. Dexa Medica Recent Development
Table 121. LG Life Sciences Corporation Information
Table 122. LG Life Sciences Description and Major Businesses
Table 123. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 124. LG Life Sciences Product
Table 125. LG Life Sciences Recent Development
Table 126. MedImmune Corporation Information
Table 127. MedImmune Description and Major Businesses
Table 128. MedImmune Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 129. MedImmune Product
Table 130. MedImmune Recent Development
Table 131. Global Tumor Necrosis Factor Inhibitors Sales Forecast by Regions (2021-2026) (K Pcs)
Table 132. Global Tumor Necrosis Factor Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 133. Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 134. Global Tumor Necrosis Factor Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 135. North America: Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 136. North America: Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 137. Europe: Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 138. Europe: Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Asia Pacific: Tumor Necrosis Factor Inhibitors Sales Forecast by Region (2021-2026) (K Pcs)
Table 140. Asia Pacific: Tumor Necrosis Factor Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 141. Latin America: Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 142. Latin America: Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 143. Middle East and Africa: Tumor Necrosis Factor Inhibitors Sales Forecast by Country (2021-2026) (K Pcs)
Table 144. Middle East and Africa: Tumor Necrosis Factor Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 145. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 146. Key Challenges
Table 147. Market Risks
Table 148. Main Points Interviewed from Key Tumor Necrosis Factor Inhibitors Players
Table 149. Tumor Necrosis Factor Inhibitors Customers List
Table 150. Tumor Necrosis Factor Inhibitors Distributors List
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Product Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Humira Product Picture
Figure 4. Enbrel Product Picture
Figure 5. Remicade Product Picture
Figure 6. Others Product Picture
Figure 7. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 8. Alzheimer's Diseases
Figure 9. Parkinson's Diseases
Figure 10. Ischemic Stroke
Figure 11. Multiple Sclerosis
Figure 12. Others
Figure 13. Tumor Necrosis Factor Inhibitors Report Years Considered
Figure 14. Global Tumor Necrosis Factor Inhibitors Market Size 2015-2026 (US$ Million)
Figure 15. Global Tumor Necrosis Factor Inhibitors Sales 2015-2026 (K Pcs)
Figure 16. Global Tumor Necrosis Factor Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region (2015-2020)
Figure 18. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Region in 2019
Figure 19. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region (2015-2020)
Figure 20. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Region in 2019
Figure 21. Global Tumor Necrosis Factor Inhibitors Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Tumor Necrosis Factor Inhibitors Revenue in 2019
Figure 23. Tumor Necrosis Factor Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type (2015-2020)
Figure 25. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Type in 2019
Figure 26. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type (2015-2020)
Figure 27. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Type in 2019
Figure 28. Global Tumor Necrosis Factor Inhibitors Market Share by Price Range (2015-2020)
Figure 29. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application (2015-2020)
Figure 30. Global Tumor Necrosis Factor Inhibitors Sales Market Share by Application in 2019
Figure 31. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application (2015-2020)
Figure 32. Global Tumor Necrosis Factor Inhibitors Revenue Market Share by Application in 2019
Figure 33. North America Tumor Necrosis Factor Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2019
Figure 36. North America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2019
Figure 37. U.S. Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Tumor Necrosis Factor Inhibitors Market Share by Type in 2019
Figure 42. North America Tumor Necrosis Factor Inhibitors Market Share by Application in 2019
Figure 43. Europe Tumor Necrosis Factor Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2019
Figure 46. Europe Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2019
Figure 47. Germany Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Tumor Necrosis Factor Inhibitors Market Share by Type in 2019
Figure 58. Europe Tumor Necrosis Factor Inhibitors Market Share by Application in 2019
Figure 59. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Market Share by Region in 2019
Figure 62. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Market Share by Region in 2019
Figure 63. China Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Tumor Necrosis Factor Inhibitors Market Share by Type in 2019
Figure 86. Asia Pacific Tumor Necrosis Factor Inhibitors Market Share by Application in 2019
Figure 87. Latin America Tumor Necrosis Factor Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2019
Figure 90. Latin America Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2019
Figure 91. Mexico Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Tumor Necrosis Factor Inhibitors Market Share by Type in 2019
Figure 98. Latin America Tumor Necrosis Factor Inhibitors Market Share by Application in 2019
Figure 99. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Market Share by Country in 2019
Figure 103. Turkey Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Tumor Necrosis Factor Inhibitors Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Tumor Necrosis Factor Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Tumor Necrosis Factor Inhibitors Market Share by Type in 2019
Figure 110. Middle East and Africa Tumor Necrosis Factor Inhibitors Market Share by Application in 2019
Figure 111. North America Tumor Necrosis Factor Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Tumor Necrosis Factor Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Tumor Necrosis Factor Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Tumor Necrosis Factor Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Tumor Necrosis Factor Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Tumor Necrosis Factor Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Tumor Necrosis Factor Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Tumor Necrosis Factor Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Tumor Necrosis Factor Inhibitors Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed

以下、関連資料のご紹介

腫瘍壊死因子α阻害剤の世界市場（～2026年）

Global Tumor Necrosis Factor Alpha Inhibitors Market Insights and Forecast to 2026
MRC2-11QY12763 2020年11月25日 117Pages
当調査資料は腫瘍壊死因子α阻害剤のグローバル市場について調査・分析したレポートです。種類別（ヒュミラ、エンブレル、レミケード、その他）市場規模、用途別（医薬品、科学研究、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、...

腫瘍壊死因子阻害薬の世界市場（～2026年）

Global Tumor Necrosis Factor Inhibitors Drug Market Insights and Forecast to 2026
MRC2-11QY12764 2020年11月25日 188Pages
当調査資料は腫瘍壊死因子阻害薬のグローバル市場について調査・分析したレポートです。種類別（Cimzia（セルトリズマブペゴル）、Enbrel（エタネルセプト）、Humira（アダリムマブ）、Otezla（アプレミラスト）、Remicade（インフリキシマブ）、Simponi（ゴリムマブ））市場規模、...

皮膚壊死治療の世界市場（～2026年）

Global Dermal Necrosis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11620 2020年11月25日 94Pages
当調査資料は皮膚壊死治療のグローバル市場について調査・分析したレポートです。種類別（免疫抑制剤、コルチコステロイド）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

無血管性壊死（AVN）の世界市場（～2026年）

Global Avascular Necrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY11000 2020年11月25日 128Pages
当調査資料は無血管性壊死（AVN）のグローバル市場について調査・分析したレポートです。種類別（外傷関連無血管壊死（AVN）、非外傷関連無血管壊死（AVN））市場規模、用途別（病院、診療所、診断センター、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イ...

神経内分泌腫瘍治療薬の世界市場（～2026年）

Global Neuroendocrine Tumor Drug Market Insights and Forecast to 2026
MRC2-11QY08112 2020年11月20日 150Pages
当調査資料は神経内分泌腫瘍治療薬のグローバル市場について調査・分析したレポートです。種類別（神経内分泌腫瘍薬mTORタンパク質阻害剤、チロシンキナーゼ3阻害剤、ソマトスタチン受容体拮抗薬、成長ホルモン放出因子拮抗薬、ソマトスタチン受容体作動薬、その他）市場規模、用途別（病院、診療所、その他）市場規模...

第IX因子欠乏症治療の世界市場（～2026年）

Global Factor IX Deficiency Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY11918 2020年11月25日 96Pages
当調査資料は第IX因子欠乏症治療のグローバル市場について調査・分析したレポートです。種類別（血友病B、血友病B阻害剤）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

低酸素誘導因子1アルファ阻害剤の世界市場（～2026年）

Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Insights and Forecast to 2026
MRC2-11QY01524 2020年11月20日 119Pages
当調査資料は低酸素誘導因子1アルファ阻害剤のグローバル市場について調査・分析したレポートです。種類別（BC-001、CASI-2ME2、CRLX-101、その他）市場規模、用途別（固形腫瘍、急性骨髄性白血病、結腸直腸癌、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギ...

脳腫瘍治療薬の世界市場（～2026年）

Global Brain Tumor Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY11184 2020年11月25日 90Pages
当調査資料は脳腫瘍治療薬のグローバル市場について調査・分析したレポートです。種類別（手術、放射線療法、標的療法、化学療法、免疫療法）市場規模、用途別（病院、腫瘍治療センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓...

凝固XI因子の世界市場（～2026年）

Global Coagulation Factor XI Market Insights and Forecast to 2026
MRC2-11QY00345 2020年11月20日 114Pages
当調査資料は凝固XI因子のグローバル市場について調査・分析したレポートです。種類別（MR-1007、IONIS-FXIRx、EP-7041、AB-022、BMS-262084、その他）市場規模、用途別（血栓症、出血・凝固障害、急性虚血性脳卒中、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ...

胎盤成長因子の世界市場（～2026年）

Global Placenta Growth Factor Market Insights and Forecast to 2026
MRC2-11QY13796 2020年11月30日 119Pages
当調査資料は胎盤成長因子のグローバル市場について調査・分析したレポートです。種類別（アフリベルセプト、アフリベルセプトバイオシミラー、SL-186、SL-188、その他）市場規模、用途別（網膜静脈分枝閉塞症、近視、血管新生緑内障、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フラ...

腫瘍壊死因子α阻害剤の世界市場（～2026年） The tumor necrosis factor alpha (TNF-a) inhibitors represent one of the major treatment methods for inflammatory diseases. Globally, this drug class is known to be the most successful drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), i…
腫瘍壊死因子阻害薬の世界市場（～2026年） Market Analysis and Insights: Global Tumor Necrosis Factor Inhibitors Drug Market The global Tumor Necrosis Factor Inhibitors Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Tumor Necrosis Factor Inhibitors Drug S…
皮膚壊死治療の世界市場（～2026年） Acute cutaneous necrosis can be defined as a skin disease with sudden onset of tissue death that results in significant morbidity and is usually, but not always, excruciatingly painful. Early diagnosis can allow for early therapy and can decrease the chances of morbidity and loss of life. A thorough…
無血管性壊死（AVN）の世界市場（～2026年） Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to interruption of the blood supply. Early on there may be no symptoms. Gradually joint pain may develop which may limit the ability to move. Complication may include collapse of the bone or nearby jo…
第IX因子欠乏症治療の世界市場（～2026年） Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B. In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market dur…